Project objectives

HIV Treatment Challenges: Rethinking the Way Forward

HIV treatment has made remarkable progress over the past decades. Yet, millions of people worldwide – especially in sub-Saharan Africa – still live without access to safe and effective therapies.

 

Today, dolutegravir (DTG) is recommended as first-line treatment by the World Health Organization (WHO).

 

Despite its highly effectiveness, questions remain about its long-term side effects, such as weight gain, diabetes, cardiovascular issues, or mental health challenges.

The ELDORADO project is based on an international clinical trial that explores new options for people starting HIV treatment.

Its main goals are to:

  • Compare the effectiveness of two drugs (doravirine (DOR) versus dolutegravir (DTG)).
  • Understand possible side effects: especially on weight, heart, liver, mental health and quality of life.
  • Explore why some people gain weight on HIV therapy, by studying cellular and metabolic mechanisms.
  • Generate evidence that can guide future HIV treatment policies worldwide.
  • Strengthen international collaboration between African, Asian, South-American and European people engaged in the fight against HIV

By producing strong and reliable evidences, ELDORADO seeks to expand therapeutic options, support health decision-makers, and globally improve the lives of people living with HIV worldwide.